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Abstract
Organismal ageing is a complex process driving progressive impair-
ment of functionality and regenerative potential of tissues. Cellular
senescence is a state of stable cell cycle arrest occurring in response
to damage and stress and is considered a hallmark of ageing. Senes-
cent cells accumulate in multiple organs during ageing, contribute
to tissue dysfunction and give rise to pathological manifestations.
Senescence is therefore a defining feature of a variety of human
age-related disorders, including cancer, and targeted elimination of
these cells has recently emerged as a promising therapeutic
approach to ameliorate tissue damage and promote repair and
regeneration. In addition, in vivo identification of senescent cells
has significant potential for early diagnosis of multiple pathologies.
Here, we review existing senolytics, small molecules and drug deliv-
ery tools used in preclinical therapeutic strategies involving cellular
senescence, as well as probes to trace senescent cells. We also
review the clinical research landscape in senescence and discuss
how identifying and targeting cellular senescence might positively
affect pathological and ageing processes.
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Introduction
Severe or irreparable cellular damage triggers a stereotyped
response across vertebrates based on a stable cell cycle arrest
known as cellular senescence. Senescent cells can implement a
complex paracrine response, including cytokines, chemokines,
growth factors, proteases and extracellular matrix remodelling
factors. This senescence-associated secretory phenotype (SASP) can
play differing roles depending on the physiological context (Mun˜oz-
Espı´n & Serrano, 2014; Pe´rez-Mancera et al, 2014). A major conse-
quence of senescence appears to prevent propagation of pre-malig-
nant cells, providing a crucial barrier to tumorigenesis (Collado &
Serrano, 2010). Cell senescence participates in other physiological
processes by promoting tissue repair and regeneration (Demaria
et al, 2014; Yun et al, 2015) and plays a programmed role in
morphogenesis during normal embryonic development in a damage-
independent fashion (Mun˜oz-Espı´n et al, 2013; Storer et al, 2013).
Senescent cells can elicit a tissue remodelling process that includes
their own elimination, recruitment of phagocytic immune cells and
mobilization of nearby progenitor cells. However, upon persistent
damage or during ageing, senescent cell clearance is compromised
and dysfunctional cells accumulate, contributing to the generation
of a chronic pro-inflammatory microenvironment that results in a
diverse range of pathological manifestations.
Cell senescence contributes to a wide variety of human age-related
pathologies, including cancer, fibrosis, cardiovascular diseases,
obesity, type 2 diabetes, sarcopenia, osteoarthritis and neurological
disorders (van Deursen, 2014; Mun˜oz-Espı´n & Serrano, 2014). The
genetic ablation of p16ink4a+ senescent cells in progeroid and chronic
disease mouse models attenuates or even reverts tissue dysfunction,
leading to an increased animal healthspan. p16ink4a+ senescent cell
clearance can ameliorate adipose atrophy, sarcopenia, cataracts,
cardiomyocyte hypertrophy, renal glomerulosclerosis, tumorigenesis,
cancer progression, atherosclerosis, osteoarthritis and tau-dependent
disease (Baker et al, 2011, 2016; Childs et al, 2016; Demaria et al,
2017; Jeon et al, 2017; Bussian et al, 2018). Importantly, such clear-
ance also increases mouse lifespan (Baker et al, 2016). For years,
pharmacological clearance of senescent cells has proved very chal-
lenging. However, in the last few years, renewed research efforts
have led to the development of senolytics, a collection of molecules
capable of preferentially removing senescent cells (Childs et al, 2017;
Soto-Gamez & Demaria, 2017; Ovadya & Krizhanovsky, 2018). Taken
together, emerging data suggest that cell senescence is causative of
multiple human disorders (Fig 1), which can be induced by various
stimuli including drugs used clinically, and that senolytics may
provide exciting opportunities for therapeutic intervention.
Besides stable cell cycle arrest and SASP production (see Fig 2
for relevant signalling pathways), another hallmark of senescent
cells is their resistance to damage-induced apoptosis through
survival pathway upregulation (Childs et al, 2014, 2017; Soto-
Gamez et al, 2019). Some senolytics exploit their capacity to stimu-
late cell death pathways (see below). In the absence of a single
universal hallmark, senescent cells can be identified by combining a
number of markers (Sharpless & Sherr, 2015), including upregula-
tion of p16ink4a and other cell cycle inhibitors, exclusion of
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proliferative markers, formation of specialized heterochromatin
domains (senescence-associated heterochromatin foci, SAHF) and
persistent activation of the DNA damage response (DDR) machin-
ery. Although imperfect, detection of increased activity of lysosomal
senescence-associated b-galactosidase (SAbgal) remains the most
widely used indicator of cellular senescence (Sharpless & Sherr,
2015), explaining why many senescence detection probes are based
on detecting its enzymatic activity.
Here, we review approaches to identify and therapeutically target
senescent cells (Fig 1). These strategies comprise senolytics and
novel drug delivery tools to target senescence. Additional innovative
interventions to manipulate cell senescence include the modulation
of the SASP and associated signalling pathways, immunotherapy
and promoting the artificial reactivation of proliferation. We discuss
novel probes for senescent cell visualization, and their potential util-
ity in medical diagnosis as well as for monitoring accumulation or
elimination of senescent cells. We comment on the clinical develop-
ment of senescence-targeted strategies and future translational
considerations, highlighting novel opportunities as well as current
challenges.
Therapeutic approaches
Senescent cells as target of therapy
Senescence and apoptosis have been proposed as alternative cell
fates in the context of damage and stress. Pro-apoptotic cellular
changes are often actively anti-senescent (Fig 2A), while senescent
Glossary
Apoptosis
Controlled cell death that occurs in response to a variety of cellular
stressors and as part of developmental programmes of multicellular
organisms.
Autophagy
Regulated mechanism used by cells to maintain homeostasis and
normal functioning by degradation of unnecessary or dysfunctional
components.
Cellular senescence
Cellular state characterized by a stable cell cycle arrest and the
implementation of a complex secretory phenotype (SASP) in response to
different sources of damage and/or stress.
Cytokines
Broad range of small secreted proteins that have specific effects on the
interactions and communications between cells and the immune system.
DDR (DNA Damage Response)
Network of cellular pathways that sense, signal and repair DNA lesions.
These include a set of DNA repair mechanisms, damage tolerance
processes and cell cycle checkpoint pathways.
Metabolic reprogramming
Molecular adjustments in metabolic pathways that alter the
bioenergetic profile and metabolism of the cell.
Nanoparticles
Particles between 1 and 100 nm in size with very large surface area to
volume ratios that can be functionalized for specific drug delivery
targeting.
Neutropenia
The abnormally low concentration of neutrophils in the blood. If severe,
it can significantly increase the risk of infection.
OIS (Oncogene-Induced Senescence)
Robust and sustained antiproliferative response that can be induced by
aberrant signalling resulting from an activating mutation of an
oncogene, or the inactivation of a tumour suppressor gene.
Osteoclastogenesis
The development of osteoclasts (cells responsible for bone break
down and resorption) from blood cells, specifically from
monocytes/macrophages.
Oxidative stress
Imbalance caused by a higher production of free radicals that cannot be
neutralized by the antioxidants produced inside the cell, resulting in
damaged components.
Progeroid (mouse) model
Genetically engineered mouse model presenting a pronounced
premature ageing and typical age-related pathologies. In particular, the
text refers to Ercc1/D mice. Ercc1 is a DNA excision repair protein
involved in genome maintenance.
Proteotoxic stress
Molecular response triggered by the accumulation of misfolded proteins
within the cell, which may impair cellular function.
Renal glomerulosclerosis
Condition that refers to the scarring or hardening of the glomeruli in the
kidney (the renal functional units). If left untreated, it can lead to kidney
failure.
Replicative senescence
State of cellular senescence induced by the attrition of telomeres in the
cells, which triggers a specific DNA damage response.
SAbgal (Senescence-associated b-galactosidase)
Lysosomal enzymatic activity increased in senescent cells that catalyses
the hydrolysis of b-galactoside into monosaccharides. It is commonly
used as a marker of cellular senescence.
SAHF (Senescence-associated heterochromatin foci)
Regions of facultative heterochromatin within the nucleus that allow
the silencing of proliferation-related genes in the cell. It is considered a
common feature of cellular senescence.
Sarcopenia
Degenerative loss of skeletal muscle mass, quality and strength
associated with ageing.
SASP (Senescence-associated secretory phenotype)
A robust secretion of molecules such as growth factors, chemokines,
cytokines and extracellular matrix metalloproteases that occurs when a
cell undergoes senescence.
Secretome
The set of all molecules and factors secreted by a cell into the
extracellular space.
Senolytic drugs
Chemical compounds that selectively target and induce the death of
senescent cells.
Senoprobes
Molecules that have been developed and engineered to analyse or
detect senescent cells for diagnostic or experimental purposes.
Synovium
Soft connective tissue that lines the inner surface of spaces of
diarthrodial joints, tendon sheaths and bursae.
Theranostic tools
Tools aimed at simultaneously detecting and eradicating a pathological
lesion or damaged area of tissue.
Thrombocytopenia
Condition associated with low blood platelet counts.
TIS (Therapy-Induced Senescence)
A subtype of cellular senescence triggered by a therapeutic treatment
such as chemotherapy or radiotherapy.
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cells are highly resistant to apoptosis. Several molecular mecha-
nisms of the senescent phenotype directly contribute to increased
survival (Fig 2B) (Childs et al, 2014; Soto-Gamez et al, 2019).
Accordingly, targeting pro-survival pathways, i.e. those involving
the BCL-2 family of proteins, the p53 or PI3K/AKT pathways
(Table EV1, Figs 2B and 3), is currently the most common strategy
to promote senescent cell elimination in damaged or aged tissues.
Inhibition of pro-survival pathways by single senolytics
Deregulation of the BCL-2 family of proteins, major regulators of
programmed cell death, is commonly observed in multiple haemato-
logical, autoimmune, degenerative disorders and cancer (Singh
et al, 2019). Navitoclax (ABT-263), a specific inhibitor of BCL-2,
BCL-xL and BCL-W, induced selective apoptosis of a variety of cells
undergoing senescence induced by ionizing radiation, oncogene
expression or replicative exhaustion, including human umbilical
vein epithelial cells (HUVECs), human lung fibroblasts and MEFs,
but not in senescent human primary preadipocytes (Zhu et al,
2016). Administration of ABT-263 also depleted senescent cells
in vivo, mitigating premature ageing of the haematopoietic system
in sublethally irradiated mice, thereby participating in bone marrow
and muscle haematopoietic stem cells rejuvenation in normally aged
mice (Chang et al, 2016). In addition, ABT-263 treatment reduced
the expression levels of several SASP factors in aged murine lungs,
Figure 1. Therapeutic and diagnostic opportunities in senescence-related disorders and during ageing.
Cellular senescence is associated with multiple human disorders, offering potential interventions for targeted therapeutic and diagnostic approaches. The development of
galactose-conjugated and fluorescent probes to detect and highlight senescent cells offers an important opportunity for longitudinal monitoring of senescence in clinical trials.
Pharmacologically active small compounds known as senolytics inhibit pro-survival pathways in senescent cells leading to apoptosis, a therapeutic strategy thatmay additionally
be enhanced by the use of immunemodulators promoting natural clearance of senescent cells. Also, a variety of drugs can manipulate the SASP and its detrimental effects, thus
suggesting a potential clinical use. Interventions to bypass senescence represent an interesting alternative, although this approach should be takenwith caution due to the risk of
uncontrolled proliferation and cancer initiation. Finally, nanoparticles encapsulating cytotoxic drugs, tracers and/or small molecules can be used as theranostic tools, both for
therapeutic and diagnostic purposes. Of note, the benefits of therapeutic approaches for the prevention or elimination of senescent cells in vivo have been validated in an
increasing number of conditions. Geneticmanipulation to inactivate the senescence pathway or to ablate senescent cells inmurinemodels produced (mostly) a beneficial impact
irrespective of the disorder or condition investigated, including adipose atrophy, cataracts, IPF, sarcopenia, kidney dysfunction, atherosclerosis, premature ageing of the
haematopoietic system, osteoarthritis, cardiomyocyte hypertrophy, loss of bone mass, type 2 diabetes, tumorigenesis, neurological disorders and natural ageing. Furthermore,
clearance of senescent cells by treatment with senolytic drugs, a more clinically relevant approach, showed in vivo benefits in, among other disorders, atherosclerosis, premature
ageing of the haematopoietic system, myocardial infarction, IPF, osteoarthritis, osteoporosis, type 1 diabetes, obesity-induced metabolic syndrome and neuropsychiatric
disorders, tau-dependent pathologies, cancer and natural ageing. IPF, idiopathic pulmonary fibrosis; HSC, hematopoietic stem cells; MuSC, muscle stem cells.
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including Cdkn2a (encoding for p16ink4a), Tnfa (encoding for TNF-
a) and Ccl5 (encoding for CCL5). In a model of articular joint injury,
the selective elimination of senescent cells in the articular cartilage
and synovium by ABT-263 reduced features of post-traumatic
osteoarthritis (Jeon et al, 2017); age-related symptoms were amelio-
rated by targeting senescent osteoblast progenitors obtained from
aged mice (Kim et al, 2017a). ABT-263 reduced the levels of several
SASP components by eliminating the senescent progenitor cells,
resulting in attenuation of osteoclastogenesis in bone marrow stro-
mal cell cultures from aged mice (Kim et al, 2017a).
ABT-737 is an analogue of ABT-263, validated in IMR90 human
fibroblasts and in mouse embryonic fibroblasts (MEFs) where the
anti-apoptotic proteins BCL-2, BCL-W and BCL-xL are highly
induced upon different senescence-inducing stimuli (Yosef et al,
2016). ABT-737 eliminated senescent cells in the lungs and epider-
mis of irradiated mice, resulting in increased hair-follicle stem cell
proliferation. However, both ABT-263 and ABT-737 are toxic for
neutrophils and platelets (Cang et al, 2015), which may limit their
clinical development. Second-generation inhibitors of the BCL-2
family of proteins include the BCL-xL inhibitors A1331852 and
A1155463, which induced selective apoptosis of senescent HUVEC
and IMR90 cells, but not of senescent human preadipocytes (Zhu
et al, 2017). Preadipocytes appear resistant to BCL2 family member
blockade, suggesting heterogeneity in cell-intrinsic senescence path-
ways (Zhu et al, 2016). These BCL-xL selective inhibitors enhance
the efficacy of standard chemotherapy in mouse models of breast
cancer, non-small-cell lung cancer (NSCLC) and ovarian cancer,
while avoiding the exacerbation of cytotoxic chemotherapy-induced
neutropenia observed with ABT-263 (Leverson et al, 2015). While
more BCL-2 family inhibitors are currently in development, target-
ing the BH4 domain is promising for enhancing senolytic sensitivity;
BH4 domain is present in all the pro-survival members of the family
(BCL-2, BCL-xL, BCL-W, MCL-1 and BFL-1) and necessary for their
anti-apoptotic activity (Liu et al, 2016).
Piperlongumine, isolated from trees of the genus Piper, is a
natural senolytic agent. Initially found to inhibit tumour growth in
a xenograft mouse model of NSCLC, it was later shown to trigger
apoptosis and preferentially kill senescent cells induced by onco-
gene expression, ionizing radiation or replicative exhaustion
(Wang et al, 2016). Panobinostat (an FDA-approved histone
deacetylase inhibitor) has senolytic activity in NSCLC, and head
and neck squamous cell carcinoma (HNSCC) cell lines previously
treated with clinically relevant cytotoxic drugs (cisplatin and pacli-
taxel) (Samaraweera et al, 2017). Panobinostat increased caspase
3/7 activity and decreased Bcl-xL expression in chemotherapy-
induced senescent cells. Recently, cardiac glycosides (CGs) have
been identified as a family of compounds with potent senolytic
activity (Guerrero et al, 2019; Triana-Martı´nez et al, 2019). CGs
target the cell membrane Na+/K+-ATPase pumps causing a disba-
lanced electrochemical gradient that makes senescent cells more
vulnerable. These compounds have been validated ex vivo in
senescent preneoplastic cells and in vivo in models of lung
fibrosis, therapy-induced senescence, and aged mice.
Combinations of drugs with senolytic activity
The tyrosine kinase inhibitor dasatinib (which inhibits SRC, c-KIT,
ephrin receptors and other kinases) and the flavonoid quercetin
(which has multiple targets including kinases and receptors, and
inhibits the PI3K-AKT pathway) are effective in combination at elim-
inating senescent cells in vitro and in vivo, selectively targeting a
wide range of senescent cell types (Zhu et al, 2015; Roos et al,
2016). A single administration of dasatinib and quercetin in aged
mice was sufficient to improve cardiovascular function and also
reduced the expression of p16ink4a and prevalence of SAbGal-posi-
tive cells after localized limb irradiation (Zhu et al, 2015). Periodic
drug administration extended healthspan in progeroid mice, delay-
ing age-related symptoms and pathologies. The combination of
dasatinib and quercetin (D + Q) in mice resulted in increased
survival and improved health. D + Q treatment prevented and alle-
viated physical dysfunction in naturally aged mice and mice trans-
planted with senescent preadipocytes, and reduced senescent cell
prevalence and pro-inflammatory cytokine secretion in explants of
human adipose tissue obtained from obese individuals (Xu et al,
2018).
It is thought that cell senescence contributes to idiopathic
pulmonary fibrosis (IPF), a progressive and debilitating chronic
disease with limited therapeutic options (Naikawadi et al, 2016). Ex
vivo treatment of mouse primary alveolar epithelial type II cells from
◀ Figure 2. Regulation of the cell cycle arrest and inflammatory SASP in the induction of cellular senescence and its interconnection with apoptosis.(A) Most senescence-inducing triggers converge in the activation of the cell cycle inhibitor pathways p53/p21 and/or p16INK4a. These result in the inhibition of cyclin-
dependent kinase 1 (CDK1), CDK2, CDK4 and CDK6, which prevents the phosphorylation of the retinoblastoma protein (RB), leading to the suppression of S-phase genes and an
ensuing stable cell cycle arrest. DNA-damaging triggers activate the DNA damage response (DDR) pathway resulting in the activation of p53 and p21. Ageing and epigenetic
derepression of the Ink4a/ARF locus also lead to the activation of cell cycle inhibitors p16 and p21. ROS lead to the activation of the MAPK signalling pathway and its
downstream effector p38. The aberrant expression of oncogenes or the loss of tumour suppressors leads to p53 activation through the Ras-Raf-MEK-ERK or AKT signalling
pathways, and TGFb, and important factor of the SASP, leads to p15, p21 and p27 upregulation via SMAD signalling. Other triggers such as developmental cues and polyploidy
activate the AKT, SMAD and/or Ras-Raf-MEK-ERK pathway for p21 upregulation, while processes such as cell fusion signal through the DDR for p53 activation. In response to
damage and different types of stress high levels of p53 with specific post-translational modifications (such as acetylated K117 and E177) target DNMT3a, a suppressor of p21
and senescence, and trigger the apoptotic programme by upregulating PUMA and NOXA, which in turn activate the caspase cascade leading to cell death. (B) SASP
implementation is orchestrated by the activation of the transcription factors NF-jB and C/EBPb through upstream signalling pathways. DNA-damaging agents, ROS and OIS,
generally activate the expression of SASP TFs via the AKT and/or the Ras-Raf-MEK-ERK axis. In addition, DNA fragments are also known to trigger the activation of the cGAS/
STING signalling, resulting in the activation of the IRF3 TF and subsequent transcription of Type 1 IFN. OIS-derived SASP is dynamic and can also be orchestrated by NOTCH
signalling, a process that restrains the inflammatory secretion by inhibiting C/EBPb at initial stages, and allows the activation of SASP-related super enhancers through NF-jB
later on. Accumulating increased levels of TFs reinforce the senescent phenotype through autocrine and paracrine signalling. SASP-derived inflammatory chemokines such as
IL-6 and IL-8 promote epigenetic modifications reinforcing the cell cycle arrest through the JAK/STAT cascade, while IL-1a stimulates the activity of NF-jB and C/EBPb
promoting a positive feedback loop on the secretion of other cytokines. Finally, senescence promotes survival networks by the regulation anti-apoptotic pathways. This
includes PI3K-AKT signalling, which can inhibit pro-apoptotic BAD and FOXO1/3, and phosphorylate caspase-9; anti-apoptotic FOXO4, that is present in senescent cells and
interacts with p53; and NF-jB, that may also promote survival responses by transcriptional induction of anti-apoptotic proteins of the Bcl-2 family. ATM/ATR, ataxia-
telangiectasiamutated and Rad3-related homologue; IFN, interferon; OIS, oncogene-induced senescence; ROS, reactive oxygen species; SASP, senescence-associated secretory
phenotype; TFs, transcription factors; TS, tumour suppressor.
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fibrotic lungs with D + Q reduced senescence and fibrosis markers
(Lehmann et al, 2017). The combination mitigated fibrotic lung
disease in a bleomycin-injury mouse model, clearing senescent cells
and improving pulmonary and physical health of treated animals
(Schafer et al, 2017). D + Q also cleared senescent cells in the
medial segments of blood vessels, improving the vascular pheno-
type associated with age-related vascular pathology (Roos et al,
2016). Likewise, chronic treatment reduced intimal aortic plaque
calcification in a hypercholesterolaemic mouse model of atheroscle-
rosis. D + Q are well-tolerated drugs and are now being trialled in
Figure 3. Therapeutic approaches targeting cellular senescence.
To prevent the deleterious effects of cellular senescence, four different strategies can be potentially implemented. The inhibition of pro-survival pathways by the use of
apoptosis-inducing drugs is a leading approach. First and second generation of inhibitors of the BCL-2 cell death regulator family of proteins can induce selective apoptosis
of senescent cells. Targeting senescence metabolism through glycolysis blockade and attenuation of ATM, HDAC, FOXO4 activities as well as the PI3K cascade have also
been reported as effective approaches. A second strategy is the activation of the immune system against senescent cells to stimulate their clearance. Enhancing the
cytotoxic activity of NK against senescent cells, and manipulating the humoral innate immunity with the use of antibodies against receptors, such as DPP4 and vimentin,
are proposed attractive strategies. Thirdly, manipulation of the SASP without compromising the cell cycle arrest of senescent cells has also proven beneficial in particular
settings. A large number of molecules can interfere with NF-jB and C/EBPb transcriptional activities or their upstream regulators, dampening the expression of SASP
factors, such as IL-1, IL-6 and IL-8, and thus reducing the senescence-derived inflammatory milieu. Lastly, genetic and epigenetic manipulation of cells, including the
induction of reprogramming, have been proposed as a means of bypassing or reverting the state of cellular senescence, although these approaches should be taken with
caution given the potential risk of cancer initiation. BCL-2, B-cell lymphoma 2; CAR, chimeric antigen receptor; GzmB, granzyme B; HDAC, histone deacetylase; HSP90, heat
shock protein 90; i4F, inducible four Yamanaka factors; LSD1, lysine-specific histone demethylase 1A; MICA, MHC class I polypeptide-related sequence A; NK, natural killer;
TERT, telomerase reverse transcriptase.
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human patients in a variety of senescence-associated conditions
(see Targeting senescence clinically in age-related disorders).
Of note, a panel of flavonoid polyphenols distinct from quer-
cetin has been screened for senolytic activity. Fisetin reduced
senescence markers in multiple tissues in progeroid and naturally
aged mice (Yousefzadeh et al, 2018), and administration of fisetin
in normally aged mice restored tissue homeostasis, reduced age-
related dysfunction and extended lifespan. Future therapeutic
outcomes will be required for initial proof of principle of combina-
tion therapies.
Targeting pathways involved in senescence
The p53 axis, another key controller of apoptosis and senescence, is
a promising target for novel senolytic strategies. FOXO transcription
factors can interact with p53, inhibiting p53-mediated apoptosis and
favouring cell cycle arrest and senescence (Wang et al, 2008). A D-
retro inverso (DRI)-isoform of FOXO4 was developed which causes
p53 nuclear exclusion and resultant death of senescent cells (Baar
et al, 2017). FOXO4-DRI selectively eliminated human senescent
fibroblasts in vitro through p53-mediated apoptosis. In naturally and
experimentally aged mice, FOXO-DRI counteracted doxorubicin-
induced senescence and chemotoxicity, minimizing hepatotoxicity
and loss of body weight, and reducing features of frailty and loss of
renal function (Baar et al, 2017).
High-throughput experimental approaches are capable of iden-
tifying novel senolytic drugs and targets. A screening platform
based on SAbgal activity identified HSP90, a ubiquitously
expressed chaperone with a role in protein stabilization, as a
potential target (Fuhrmann-Stroissnigg et al, 2017). HSP90 inhibi-
tors downregulate the anti-apoptotic PI3K/AKT pathway and
reduce senescence markers in a variety of human and mouse cell
lines. In a progeroid mouse model, the HSP90 inhibitor 17-DMAG
[alvespimycin, which has been tested in clinical trials in different
solid tumours and lymphomas (Trepel et al, 2010)] reduced
p16ink4a expression levels, extended healthspan and delayed the
onset of various age-related clinical markers (Fuhrmann-Stroiss-
nigg et al, 2017). A similar high-throughput screening approach
identified KU-60019, an inhibitor of the DDR protein ataxia-telan-
giectasia mutated (ATM), as an effective anti-senescent agent
(Kang et al, 2017). ATM can mediate mechanisms that control
senescence through regulating lysosomal acidification. Treatment
with KU-60019 decreased SAbgal activity in senescent fibroblasts,
removed dysfunctional mitochondria and resulted in metabolic
reprogramming. KU-60019 therapy accelerated cutaneous
wound healing in aged mice, and inhibition of ATM activity
also attenuated senescence (Kang et al, 2017); KU-60019 is there-
fore a promising candidate target for treatment of age-related
diseases.
Senescent cells are “hypermetabolic”, and this may potentially
be therapeutically targetable (Do¨rr et al, 2013). Metabolic repro-
gramming is required for senescent cells to cope with the high ener-
getic demands of the senescent programme, including SASP-coupled
proteotoxic stress (featured by high production of SASP factors,
increased oxidative stress resulting in misfolded or toxic proteins,
and increased endoplasmic reticulum stress/unfolded protein
response/ubiquitination/autophagy cascade). Accordingly, senes-
cent cells are more sensitive to treatment with 2-DG, a decoy
substrate for glycolytic metabolism or specific inhibitors of
lysosomal V-ATPases (Do¨rr et al, 2013). How metabolically targeted
drugs can achieve sufficient specificity for senescent over non-senes-
cent cells in vivo to allow successful translation remains an open
question.
Manipulation of the SASP
Although inducing the selective apoptosis of senescent cells using
senolytic drugs could be therapeutically beneficial, dampening the
detrimental effects of the SASP without compromising senescent cell
cycle arrest may prove more advantageous in particular settings.
Seminal work showing that the SASP and cell cycle arrest are inde-
pendently regulated (Coppe´ et al, 2011) opened the door to differen-
tially targeted therapeutic approaches. Senescent cells implement
programmed secretion of growth factors, matrix metalloproteases,
chemokines and cytokines that can trigger a wide range of autocrine
and paracrine effects. Some of these [such as immune activation
and reinforcement of growth arrest and differentiation (Hong et al,
2007; Anestakis et al, 2015)] are crucial for the resolution of tissue
damage, but others (such as cell growth, migration and invasion)
can be disadvantageous in certain contexts including cancer (Pe´rez-
Mancera et al, 2014; Gonzalez-Meljem et al, 2018; Lee & Schmitt,
2019). Activation of various signalling pathways, including key
drivers such as mammalian target of rapamycin (mTOR), mitogen-
activated protein kinase (MAPK) signalling, phosphoinositide 3
kinase (PI3K) signalling and GATA4/p62-mediated autophagy,
orchestrates this complex secretome (reviewed in Faget et al, 2019)
(Fig 2B). These cascades converge in the activation of the NF-jB
and the CCAAT/enhancer binding protein beta (C/EBPb) pathways.
The great diversity of potential targets able to modulate the cascades
driving the expression of the SASP prompted the development of a
number of molecules and antibodies to interfere with NF-jB and C/
EBPb transcriptional activities at different levels (Table EV2 and
Fig 3).
Modulation of the upstream regulators of NF-jB activity
mTOR is a serine/threonine kinase implicated in a wide variety of
cellular processes. It is thought to interact with the MAPK pathway
by increasing the translation of MAPKAPK2 (Herranz et al, 2015),
ultimately resulting in NF-jB activation and nuclear translocation.
mTOR can also regulate membrane-bound IL-1a expression
(Laberge et al, 2015), rendering it an attractive target for selective
inhibitors. mTOR inhibition by rapamycin in normal human fibrob-
lasts and non-tumorigenic human breast cells suppresses the secre-
tion of inflammatory cytokines including IL-6, and selectively
decreases IL-1a translation, thereby diminishing NF-jB transcrip-
tional activity (Laberge et al, 2015). Rapamycin also suppresses the
ability of senescent fibroblasts to stimulate prostate tumour growth
in mice (Imrali et al, 2016) and blocks the translation of
MAPKAPK2, leading to degradation of several SASP components
transcripts, including IL-8 and IL-1a (Herranz et al, 2015). Treat-
ment of murine lung WI-38 fibroblasts with rapamycin resulted in a
significant decrease in IL-6, IL-1b and Vcam-1 transcription and
decreased Stat3 pathway activation (Wang et al, 2017). Newer
mTOR inhibitors with comparatively advantageous pharmacological
properties have been developed and may also target detrimental
effects of the SASP (Lamming et al, 2013; Leontieva et al, 2015).
The effects of such “rapalogs”, including everolimus, temsirolimus
and deforolimus on senescence remain however unclear.
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Inhibitors of members of the MAPK pathway have also been inves-
tigated as SASP modulators. The p38MAPK inhibitor SB203580
reduces mRNA levels and secretion of several SASP components
reducing NF-jB transcriptional activation and paracrine effects of
the SASP in human senescent cells (Freund et al, 2011). The
next-generation p38MAPK inhibitors UR-13756 and BIRB 796 also
suppress IL-6 expression in human senescent fibroblasts, and treat-
ment of cells with the MAPKAPK2 inhibitors PF-3644022 and MK2.III
attenuates the SASP (Alimbetov et al, 2016). In addition, treatment of
astrocytes with ginsenoside F1, an enzymatically modified derivative
of ginsenoside Rg1 that targets p38MAPK, robustly decreased IL-6 and
IL-8 secretion (Hou et al, 2018). Conditioned media from senescent
astrocytes treated with ginsenoside F1 were less able than controls to
induce paracrine-activated cell migration of glioblastoma cells.
Nutlin-3a results in p53 stabilization by inhibiting Mdm2 and was
shown to inhibit the activity of NF-jB in a p53-dependent manner
(Dey et al, 2008). Nutlin-3a is therefore an attractive anti-cancer ther-
apy since it could simultaneously activate p53 and suppress NF-jB.
Indeed, the cytokine response to DDR requires ATM, NBS1 and
CHK2, but not the cell cycle arrest enforcers p53 and pRb (Rodier
et al, 2009). Nutlin-3a treatment of human fibroblasts not only
decreased the secretion of certain SASP interleukins, but the collected
conditioned medium was able to suppress breast cancer cell invasive-
ness (Wiley et al, 2018). MI-63, a next-generation Mdm2 inhibitor,
showed similar results (Wiley et al, 2018), confirming the potential
of these drugs to attenuate detrimental paracrine effects of the SASP.
Many Mdm2-MdmX inhibitors have entered clinical trials with the
hope of restoring p53 function in a variety of malignancies; thus far,
no drugs in this class have been approved.
Direct modulation of NF-jB binding and activity
Metformin is a well-tolerated drug used extensively in treatment of
type 2 diabetes. It reduces NF-jB nuclear translocation, preventing
the activation of the NF-jB pathway, and has been extensively inves-
tigated as a possible SASP modulator (Moiseeva et al, 2013). Treat-
ment of Ras-mutant IRM-90 fibroblasts with metformin significantly
inhibited the secretion of several SASP components, including CXCL-
5, IL-6, IL-8 and IL-1b, by interfering with IKK/NF-jB activation
(Moiseeva et al, 2013). In addition, metformin activates AMPKa,
resulting in mTOR signalling pathway inhibition (Sinnett-Smith et al,
2013). Resveratrol (Pitozzi et al, 2013) and the flavonoids wogonin,
kaempferol and apigenin (Lim et al, 2015; Perrott et al, 2017) are
natural compounds thought to interfere with NF-jB through their
interaction with IjB kinases and effectively attenuate the SASP in
specific contexts. Glucocorticoids, steroid hormones with potent
anti-inflammatory activity, can also suppress the SASP by modulat-
ing NF-jB transcriptional activity. Treatment with cortisol and corti-
costerone suppressed the secretion of several SASP components,
including IL-6 and IL-1a, impairing the ability of the SASP to stimu-
late breast cancer cell invasion in vitro (Laberge et al, 2012).
Modulation of the upstream regulators of C/EBPb activity
SASP-derived pro-inflammatory effects are linked to JAK/STAT
pathway activation, which may sustain cytokine production by acti-
vation of the transcription factor C/EBPb (Faget et al, 2019). Treat-
ment of irradiation-induced senescent adipocytes with the JAK1/2
inhibitor ruxolitinib significantly reduced SASP factor secretion (Xu
et al, 2015). Ruxolitinib treatment of aged mice notably diminished
systemic and adipose tissue inflammation and improved mice fit-
ness, demonstrating anti-inflammatory potential for treatment of
chronic disorders. Additionally, oncogene-induced senescence is
accompanied by dynamic fluctuation of NOTCH1 ligand activity,
driving a TGF-b-rich secretome while suppressing the pro-inflamma-
tory SASP through C/EBPb repression (Hoare et al, 2016). NOTCH1
is upregulated within NRAS-senescent hepatocytes and negatively
controls senescence immunosurveillance promoting tumorigenesis.
Modulation of this pathway should be considered in potential
cancer therapeutic translation.
Other ways of modulating the SASP
Other potential SASP-associated targets have been reported, includ-
ing the alternative splicing modulator polypyrimidine tract binding
protein 1 (PTBP1), which regulates a pro-inflammatory secretome.
Inhibition of PTBP1 attenuated SASP-induced tumour promotion in
a mouse model of hepatocellular carcinoma (Georgilis et al, 2018).
PTBP1 may therefore be a potential therapeutic target.
Targeting of specific components of the SASP known to be dele-
terious in certain conditions could provide more precise, potentially
biomarker-directed, therapeutic strategies, including through
neutralization of well-defined cytokines (such as IL-1, IL-6 or IL-8 or
their receptors) by monoclonal antibodies. Although such antibodies
have been developed (van Rhee et al, 2014), their effects on senes-
cence-associated phenotypes remain uncertain. Intriguingly, canaki-
numab, a monoclonal antibody directed against IL-1b and approved
for the treatment of cryopyrin-associated periodic syndrome and
other rare autoinflammatory disorders, has been investigated in a
number of more common inflammatory disorders—these disorders
are linked with senescence and their true mechanism of action may
lie in the SASP modulation. Of note, in the phase 3 CANTOS clinical
trial for ischaemic heart disease (NCT01327846), patients treated
with canakinumab had a very significantly reduced risk of being
subsequently diagnosed with lung cancer (Ridker et al, 2017). Since
pre-malignant lung adenomas are characterized by accumulation of
senescent cells (Collado et al, 2005), it is tempting to speculate that
senescent cells are targeted specifically by canakinumab.
Immune activation to target senescent cells
The immune system plays a fundamental role in senescent cell
clearance and it is thought that the age-dependent decline of the
immune system is partially responsible for the accumulation of
senescent cells in tissues over time. Clearance of senescent cells is
driven by CD4(+) T cells and monocytes/macrophages through a
process known as senescence surveillance (reviewed in Burton &
Stolzing, 2018). Natural killer (NK) cells can mediate elimination of
senescent hepatic stellate cells in a model of damage-induced liver
fibrosis, resulting in less fibrotic scarring and facilitating fibrosis
resolution (Krizhanovsky et al, 2008). Accordingly, administration
of polyinosinic–polycytidylic acid (polyI:C; a NK Toll-like receptor 3
[TLR3] ligand) and interferon-c enhances the cytotoxic activity of
NK cells against activated hepatic stellate cells and ameliorates liver
fibrosis (Radaeva et al, 2006). This process appears to be mediated
by activation of the NK cell receptor NKG2D, which recognizes
ligands on the surface of infected, damaged or stressed cells.
Ligands of NKG2D are elevated in senescent cells, and NKG2D was
required for NK cell-mediated senescent cell clearance protecting
against liver fibrosis (Sagiv et al, 2016).
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Activation of antibody-dependent cell-mediated cytotoxicity
(ADCC) may also preferentially eliminate senescent cells. The
surface peptidase DPP4 is enriched on senescent human diploid
fibroblasts versus normal cells. An anti-DPP4 antibody triggered
ADCC via NK cells, which eliminated senescent cells in vitro (Kim
et al, 2017b). An oxidized form of membrane-bound vimentin was
recently described as a novel marker for senescent murine lung
fibroblasts (Frescas et al, 2017). The resultant hypothesis that
humoral innate immunity may recognize and target the oxidized
form of vimentin in senescent fibroblasts is yet to be tested in vivo.
A variety of new interventions focused on the activation of the
immune system have emerged as effective treatments for a wide
variety of diseases. Since senescent cells are immunogenic, reactiva-
tion of immune cell effector mechanisms against these cells, or
senescent cell manipulation to increase their immunogenicity, are
attractive clinical development strategies.
Bypassing and reverting senescence
Although cell senescence was originally described as an irreversible
cell cycle arrest, in vitro reactivation of cell proliferation after induc-
tion of senescence can be achieved. For example, enforced telom-
erase activity induces the bypass of replicative senescence without
inactivation of the p16ink4a/Rb pathway or abrogation of p53 expres-
sion (Pellegrini et al, 2004). In an OIS model, IL-6 exerts an antipro-
liferative effect, and its depletion allows cells to bypass OIS. This
phenomenon was associated with the suppression of p15INK4B
(Kuilman et al, 2008). Inhibition of the chemokine receptor CXCR2
also alleviates replicative senescence and OIS (Acosta et al, 2008).
Ectopic overexpression of the polycomb group (PcG) protein CBX8,
required for proliferation of diploid human and mouse fibroblasts,
also allows senescence bypass and immortalizes primary MEFs
through direct repression of the Ink4a-Arf locus (Dietrich et al,
2007). In a seminal study, in vivo reprogramming of somatic cells
was shown to restore their proliferative potential (Abad et al, 2013),
a relevant approach for future applications in tissue repair and
regenerative medicine. Interestingly, pools of cells enriched in
senescent cells from centenarians were reprogrammed in vitro to
pluripotent stem cells (Lapasset et al, 2011).
These studies open up the possibility of bypassing senescence ther-
apeutically. However, such approaches should be considered with
caution. A recent study showed that therapy-induced senescent (TIS)
cells can acquire both functional and phenotypic stemness features in
in vivo models of lymphoma and leukaemia, developing stronger and
more aggressive tumour growth potentials (Milanovic et al, 2018). In
this pioneering work, lymphoma cells that escaped a previously senes-
cent state presented a higher tumour-initiating capacity than cells that
were never senescent, and this feature was driven by the activation of
the canonical Wnt signalling pathway in TIS. This experimental
approach used mice carrying loss-of-function alleles at the Suv39h1
locus, and it remains to be seen if the required epigenetic changes asso-
ciated with reversion of cellular senescence occur in nature.
Probes for diagnosis
Senescent cells have increased lysosomal content, with high levels
of lysosomal b-galactosidase, a feature used for decades to highlight
senescent cells in vitro and in vivo (Sharpless & Sherr, 2015).
Multiple fluorescent probes for tracking b-galactosidase activity
have been developed over the last years. Although having the
potential to target senescent cells, many probes have been validated
only in human cells transfected with plasmids harbouring the
Escherichia coli lacZ gene, resulting in cytoplasmic overexpression
of bacterial b-galactosidase. However, this approach does not reca-
pitulate cellular senescence, as it does not correspond with the
endogenous lysosomal b-galactosidase activity associated with
senescence. Also, some probes have been tested in particular
human cancer cell lines naturally expressing high levels of lysoso-
mal b-galactosidase (Table EV3). Here, we focus on fluorescent
probes validated in bona fide senescent cells/tissues. We believe
these sets of probes to be the most promising for translation to
in vivo models of senescence-related disorders and/or the accumula-
tion of senescent cells during ageing (see Table EV3 and Fig 4).
Fluorescent probes validated in vitro
The first reported ratiometric two-photon fluorescent probe to track
senescent cells in vitro, initially tested in human diploid fibroblasts
(HDFs) undergoing replicative senescence, consists of a naph-
thalene-based fluorescent moiety (SG1) containing a b-D-galactopyr-
anoside-derived benzyl carbamate at the b-gal hydrolytic site and a
solubilizing group (Lee et al, 2014). This probe produces a blue-to-
yellow emission response to b-gal and has high insensitivity to pH
and reactive oxygen species, high photostability and low cytotoxic-
ity. Gal-Pro, another senescence-specific fluorescent probe, was
recently validated in vitro using HDFs undergoing oxidative stress-
induced senescence (Zhang et al, 2017). Gal-Pro is based on a hemi-
cyanine skeleton conjugated with a D-galactose residue via a glyco-
sidic bond displaying near-infrared emission. The probe exhibited a
rapid and sensitive turn-on response to SAbgal in living cells, with
high photostability and low background fluorescence.
Fluorescent probes validated in vivo
The fluorescent probe AHGa can trace senescent cells in vivo in
mice bearing human melanoma SK-MEL-103 tumour xenografts
treated with senescence-inducing chemotherapy (Lozano-Torres
et al, 2017). AGHa is an OFF-ON two-photon fluorescent probe
comprising a naphthalimide fluorophore, an L-histidine methyl ester
linker and an acetylated galactose bonded to one of the aromatic
nitrogen atoms of the L-histidine through an N-glycosidic bond that
can be hydrolysed by b-galactosidase activity. Whereas tumours of
mice treated with palbociclib (a potent senescence-inducing CDK4/6
inhibitor) and injected intravenously with AHGa displayed a clear
fluorescent signal, tumours of untreated mice showed negligible flu-
orescence, and the probe was not activated significantly in endoge-
nous tissues. The combination of selectivity, sensitivity and
straightforward synthesis makes AHGa an efficient and attractive
OFF-ON two-photon probe for the in vitro and in vivo imaging of
senescence. NIR-BG is an activatable molecular probe synthesized
by glycosylation of a hemicyanine dye and a protected galactosyl
bromide, with far-red excitation, near-infrared emission and high
turn-on ratio upon SAbgal activation (Wang et al, 2019). This probe
was validated in a variety of human cancer cells (HeLa and MCF7)
undergoing camptothecin and/or radiation-induced senescence,
and also in mice bearing HeLa xenografted tumours under-
going chemotherapy-induced senescence. HMRef-bGal is a highly
membrane permeable and b-gal-sensitive fluorescence probe, which
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Figure 4. Novel diagnostic and therapeutic approaches for targeting senescent cells: probes and nanoparticles.
(A) Representative structural images of some of the novel tools developed for the detection and targeting of senescent cells. Diagnostic probes are either fluorescent or
chromogenic and can be detected upon b-galactosidase catalytic reaction. Nanocarriers are loaded or tagged with either fluorescent particles (such as rhodamine) or drugs/
senolytics (doxorubicin, navitoclax, rapamycin) for different clinical interventions. Most of the senescence-directed nanoparticles are coated or conjugated to galactose-
derived residues or have been designed to bind to specific receptors. (B) Tracking the b-galactosidase activity of senescent cells is one of the commonest strategies for the
development of probes and nanoparticles. The enzymatic activity cleaves galactose residues conjugated to endocytosed probes or nanoparticles and allows the release of
carriers or the emission of colour/fluorescence within the lysosomal compartment. Other developed tools can bind to receptors present on the membrane to either allow the
detection of senescent cells (Nano-MIPs) or subsequently become endocytosed and processed by b-galactosidase activity (CD9-mAb-coated nanoparticles). B2M, beta-2
microglobulin; b-gal, b-galactosidase; GalNPs, 6-mer galacto-oligosaccharides-conjugated nanoparticles; GosNPs, galacto-oligosaccharides-conjugated nanoparticles; MIPs,
molecularly imprinted particles; NPs, nanoparticles; PEG, polyethylene glycol.
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utility was demonstrated for in vivo visualization of small tumours
initiated by intraperitoneal injection of different ovarian cancer cells
expressing endogenous high levels of lysosomal b-gal (Asanuma
et al, 2015). HMRef-bGal remains untested in senescence itself.
HMRef-bGal is based on a spirocyclization strategy that uses a
hydroxymethyl rhodol derivative bearing a b-gal moiety.
Development of fluorescent probes to track b-gal activity thus
represents an innovative approach to monitor senescent cells in vivo
for potential bioimaging applications. However, clinical applications
of fluorescent probes are still challenged by a limited tissue penetra-
tion depth (~1 cm), which makes them more suitable for specific
tissues, such as the skin. We await next-generation probes for senes-
cence monitoring, which may include activatable contrast agents
(for MRI detection) and radiotracers (for PET detection). Galacto-
conjugation of PET radionuclides could then be an interesting
approach to track senescent tissues in vivo.
Nanoparticles as diagnostic and therapeutic tools
Nanomedicine is an innovative approach for cell type-/biomarker-/
phenotype-specific cargo delivery. Although the technological success
achieved in this field is considerable, incomplete knowledge of nano-
bio interactions and nanoparticle biodistribution in mammals, poten-
tial toxic effects, clearance pathways and challenges with scaling up
the manufacturing process have impeded the translational applica-
tions and commercial development of various promising formula-
tions. Nevertheless, their specificity in cell targeting and versatility in
cargo encapsulation makes them ideally suited for modulation/elimi-
nation of senescent cells (Table EV4 and Fig 4).
The first targeted cargo delivery system for senescent cells was
based on functionalized mesoporous silica nanoparticles (NPs)
(Agostini et al, 2012). Here, spherical particles (~100 nm size)
encapsulating rhodamine were coated with galacto-oligosaccharides
of different lengths (Gos), preventing the release of the cargo out of
a silica matrix known as MCM-41. Cellular uptake of GosNPs occurs
via endocytosis, and, after fusion with lysosomal vesicles, the beads
are eventually released by exocytosis. Preferential release of rhoda-
mine in SAbgal-positive human senescent fibroblasts from dysker-
atosis congenita patients was observed, but not in (control)
proliferative human NSCLC cells.
This silica bead-based nanotechnology was recently refined by
using a homogenous coating consisting of a 6-mer galacto-oligosac-
charide (Gal) and validated in models of damage-induced and
chemotherapy-induced senescence (Mun˜oz-Espı´n et al, 2018). It was
reported that gal-encapsulated rhodamine, GalNP(rho), is preferen-
tially released in a variety of human cancer cell lines (including mela-
noma, head and neck squamous cell carcinoma and NSCLC cells)
undergoing palbociclib-induced senescence. GalNP(rho) was selec-
tively activated in senescent lesions in vivo, using palbociclib-treated
tumour xenografts and fibrotic lungs damaged by bleomycin. In the
latter case, lung epithelial cells and fibroblasts exhibiting enriched
signatures of senescence label with rhodamine preferentially upon
GalNP(rho) administration when compared with control mice.
In addition to cell labels, nanoparticles can encapsulate small mole-
cules capable of killing senescent cells, potentially widening the thera-
peutic window of these agents (Table EV4 and Fig 4). Gal-encapsulated
doxorubicin, GalNP(dox), induced apoptosis in palbociclib-induced
senescent cells, but not in control (proliferative) cells, thus validating
its therapeutic senescence-targeting potential (Mun˜oz-Espı´n et al,
2018). Of note, GalNP(dox) treatment restored lung function in mice
with bleomycin-induced pulmonary fibrosis and reduced the lung
fibrotic scar. In addition, GalNP(dox) promoted tumour regression in
combination with palbociclib in mice bearing tumour xenografts of
human squamous cell carcinoma or melanoma cells. Besides
chemotherapy drugs, encapsulation of senolytics should increase their
therapeutic specificity. A combination of palbociclib and galacto-encap-
sulated navitoclax also reduced tumour xenograft growth, reinforcing
the concept that this nanotechnology is an efficient therapeutic tool to
specifically deliver drugs into senescent cells. Reassuringly, galacto-
encapsulation diminished undesirable toxicities of doxorubicin and
navitoclax (cardiotoxicity and thrombocytopenia, respectively). Collec-
tively, studies with GalNP nanocarriers provide an important and
versatile advance in the ability to deliver small compounds to multiple
types of senescent lesions in vivo, providing proof of concept of poten-
tial therapeutic and diagnostic applications in the clinic.
Porous calcium carbonate nanoparticles (CaCO3, ~130 nm size)
loaded with rapamycin have also been used to target senescent cells
(Thapa et al, 2017). CaCO3(Rapa) NPs were wrapped with a conjugate
of lactose (Lac; to facilitate cargo release by lysosomal b-galactosidase
activity), and polyethylene glycol (to stabilize carriers in blood and
prevent opsonization). Lac/CaCO3(Rapa) NPs were functionalized
with a monoclonal antibody against CD9, a cell surface glycoprotein
receptor overexpressed in senescent cells, to further promote senescent
HDF targeting. Treatment of HDFs with CD9-Lac/CaCO3(Rapa)
resulted in anti-senescence effects as defined by decreased b-gal and
p53/p21/CD9/cyclin D1 expression, reduced population doubling
time, enhanced cell proliferation/migration, reduced expression the
SASP components and prevention of cell cycle arrest. Calcium carbon-
ate nanoparticles loaded with a coumarin fluorescent dye, CD9-Lac/
CaCO3(C9H6O2), exhibited high cellular uptake by senescent HDFs,
indicating that this nanotechnology is also suitable for imaging senes-
cence. In another study, pretreatment of human aortic endothelial cells
with molybdenum disulphide nanoparticles (MoS2 NPs) inhibited
H2O2-induced senescence by preventing lysosomal and mitochondrial
dysfunction (Ke et al, 2018). Exposure to MoS2 NPs promoted autop-
hagy in these cells, resulting in improved endothelial cell functionality.
Interestingly, another recent study shows that molecularly imprinted
nanoparticles (nanoMIPs) can be designed to target epitopes of surface
proteins in senescent cells, such as b2 microglobulin (B2M) in senes-
cent EJ bladder cells (Ekpenyong-Akiba et al, 2019). NanoMIPs were
internalized after B2M-binding and had a cytotoxic effect when loaded
with the senolytic dasatinib. Fluorescently tagged nanoMIPs detected
senescent cells in the abdominal cavity of naturally aged mice, while
no signs of toxicity were found at a single dose.
Nanoparticles therefore offer a versatile and novel strategy for
in vitro and in vivo targeting of senescent cells with potential diag-
nostic and therapeutic applications, including as theranostic tools,
aimed at simultaneously detecting and eradicating senescent lesions
associated with age and numerous human pathologies.
Targeting senescence clinically in age-related disorders
Elimination of senescent cells can ameliorate and even reverse a
variety of age-related disorders in preclinical studies (Mun˜oz-Espı´n
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& Serrano, 2014; Childs et al, 2017; Soto-Gamez & Demaria, 2017;
Ovadya & Krizhanovsky, 2018), holding exciting promises for the
development of novel therapeutic strategies against these important
pathologies (Fig 1). To this end, clinical trials are in progress where
senescent cells are the therapeutic targets of systemically delivered
small molecules (Table EV5). Encouraged by successful preclinical
results, the combination of D + Q is being tested in some age-related
disorders, including chronic kidney disease, which has multiple
systemic consequences (NCT02848131), idiopathic pulmonary
fibrosis (NCT02874989) and in haematopoietic stem cell transplant
survivors who are at increased risk of premature ageing
(NCT02652052).
Most approved cancer therapeutics are designed to eliminate
tumour cells by inducing apoptosis. The critical regulator of apop-
tosis, Bcl-2 (target of navitoclax), is overexpressed in the majority
of small cell lung cancer (SCLC) tumours (Ikegaki et al, 1994).
Although correlative analyses suggested several putative biomark-
ers of clinical benefit, navitoclax showed limited efficacy as a
single agent in advanced and recurrent SCLC (Rudin et al, 2012),
suggesting these tumours are not sensitive at steady state and do
not have high senescent cell burden, or that sufficient senolytic
concentrations were not achieved. Besides promoting apoptosis,
many of the standard chemotherapies and targeted therapies used
in the clinic can also induce senescence in tumour cells (Ewald
et al, 2010; Petrova et al, 2016), which may be important for at
least a portion of therapeutic resistance. TIS translates into slower
proliferation rates, but the SASP produced by senescent cells can
potentially promote an invasive phenotype and an increased
growth in neighbouring non-senescent tumour cells (Pe´rez-
Mancera et al, 2014; Gonzalez-Meljem et al, 2018). Combining
standard senescence-inducing chemotherapies with senolytic
agents therefore represents an attractive approach for treating
solid tumours. Several phase 1 and phase 1/2 clinical trials
combining senescence-inducing chemotherapies or targeted thera-
pies with navitoclax are ongoing or completed, including with
cisplatin, etoposide and navitoclax in SCLC patients
(NCT00878449), dabrafenib, trametinib and navitoclax treating
patients with BRAF mutant metastatic melanoma (NCT01989585),
and osimertinib and navitoclax in patients with EGFR-positive
advanced NSCLC (NCT02520778). Navitoclax is also combined
with gemcitabine (NCT00887757), paclitaxel (NCT00891605),
docetaxel (NCT00888108), irinotecan (NCT01009073), erlotinib
(NCT01009073), sorafenib (NCT02143401) or trametinib
(NCT02079740) in advanced solid tumours. Two trials from the
last group have already published results in small subsets of
patients with varying solid tumours. A total of forty-six patients
were treated with gemcitabine and a dose escalation of navitoclax
(NCT00887757), demonstrating good tolerability and safety for the
combination, but no objective responses were observed (Cleary
et al, 2014). A total of eleven patients received the combination
of navitoclax and the tyrosine kinase inhibitor erlotinib
(NCT01009073), which was also well tolerated but did not result
in any objective responses (Tolcher et al, 2015). Another phase 1
study combining navitoclax with carboplatin/paclitaxel in nineteen
patients with solid tumours showed modest efficacy (Vlahovic
et al, 2014).
In these cases, based on heterogeneous cancer-type patient
cohorts, analyses were exploratory, and hence, conclusions on the
efficacy should be taken with caution. It is not clear if objective
responses were not observed because (i) the tested chemotherapies
did not induce senescence in these patients; (ii) senolytics did not
achieve sufficient intratumoural concentrations; (iii) senolytics were
ineffective at killing senescent cells; (iv) cancer-type specificities
were not representative of preclinical models; or (v) a combination
of these/other factors. It is, however, imperative to persist in the
approach: future studies should explore promising targeting agents
where senescence induction is known to be robust in human
patients with specific cancer types well represented by appropriate
preclinical models. Embedding translational science into these trial
protocols, with the analysis of senolytic effects on pre- and post-
treatment biopsies, or the use of senescent cell imaging approaches,
should help refine strategies and direct them to patients most likely
to benefit.
Age-related immune senescent remodelling is likely to contribute
to the decline of the immune system, chronic inflammatory state,
risk for frailty, chronic disease and functional decline in older indi-
viduals (Akbar et al, 2016). Patients with activated PI3K Delta
syndrome present a dominant mutation in the PI3K catalytic subunit
p110d, resulting in T-cell senescence and immunodeficiency (Lucas
et al, 2014). Administration of a selective PI3Kd inhibitor leniolisib
(CDZ173) showed a reduction of senescent T cells and a decrease in
inflammatory markers in a trial involving six patients
(NCT02435173), and an extension study is ongoing (NCT02859727).
Treatment of mice with metformin is associated with a reduction
in oxidative stress and inflammation, resulting in extension of lifes-
pan and healthspan (Barzilai et al, 2016). Three clinical trials in
older patients are evaluating the premise that metformin may be an
effective “anti-ageing” drug (NCT02325245, NCT02570672 and
NCT03451006), with changes in frailty indices as their primary
outcome measures. A fourth clinical trial (NCT02432287) tests the
hypothesis that metformin will result in changes in the transcrip-
tome, reverting the expression profiles of older adults with impaired
glucose intolerance towards those seen in younger patients, in
muscle and adipose tissue. A phase 3 clinical trial (NCT03309007)
aims to investigate the effects of a short treatment with metformin
on cellular senescence and autophagy in older adults with pre-
diabetes. Confirming initial hypotheses of improvements seen in
autophagy and senescence would justify starting further clinical
trials with metformin as an anti-ageing therapy, but these should
ideally be in disease-specific populations with objective, clinically
relevant endpoints.
A phase 2 clinical trial (NCT02874924) is measuring effects of
rapamycin (sirolimus) in patients over 70 years old on general
parameters of immune health, including levels of inflammatory
serum cytokines and polyclonal T-cell activation. Secondary
outcomes include improvement in physical, cognitive and cardio-
vascular functions. A phase 1 clinical trial (NCT01649960) involving
low-dose rapamycin in older adults with coronary artery disease has
already been completed, with the assessment of frailty by physical
performance as a primary outcome, and the analysis of the SASP
and quantification of the levels of senescent preadipocytes as
secondary outcomes. Other approaches are in development, includ-
ing a further trial (NCT03353597) evaluating the effects of monthly
plasma transfusions of young healthy male donors to older subjects
(> 40) in order to reverse epigenetic and other markers of senes-
cence. The outcomes of the study are the assessment of cell DNA
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methylation levels to calculate an epigenetic age, as well as detec-
tion of changes in cognitive, renal and pulmonary function, muscle
strength, telomere length and expression levels of IGF-1 and
p16INK4a in blood and skin biopsies.
Despite the increasing prevalence and societal burden of age-
related diseases, trials targeting senescence are still relatively few in
number, and we await an objective initial proof of principle. It is
important that we reassess the best way to translate promising
preclinical observations into well-designed translational approaches
and effective therapeutic strategies. Importantly, a number of
Biotechnology Companies are now developing translational activi-
ties in the field of senescence including, among others: Unity
Biotechnology (Bcl-2 inhibitors), Senolytic Therapeutics (NPs to
target SAbgal-positive cells), Oisin biotechnologies (NPs to target
p16-positive cells), Antoxerene (FOXO4 peptides), CellAge (multi-
genic senescence signatures), and Everon Biosciences and Siewa
Therapeutics (senescence immunotherapy strategies).
Future perspectives
This review recapitulates a collection of innovative approaches to
manipulate and trace cellular senescence, including some already
tested and validated in animal models of human pathologies and a
number of ongoing studies in humans. Successful clinical transla-
tion of strategies targeting senescent cells may have a significant
impact on the treatment of multiple human age-related disorders, as
well as increase lifespan and healthspan by delaying the chronologi-
cal ageing of damaged tissues and organs. Nevertheless, several
important challenges must be considered to optimize translation of
senescence-targeted therapeutic strategies to the clinic.
Human cell cultures have provided considerable data on
senotherapies (see Tables EV1 and EV4) and senoprobes (see
Table EV3). Approaches have employed a variety of senescence-
inducing stressors, different cell types and different regulatory
mechanisms. However, most approaches have excluded the
complex 3D microenvironment of diseased tissues in living organ-
isms, and their relevance for translation to human diseases remains
therefore unclear. The method used to induce senescence (replica-
tive stress, oncogene activation, damaging compounds, irradiation,
carcinogens, etc.) strongly determines the key drivers and the
signalling pathways involved, a process that is also critically depen-
dent on the cellular type and tissue of origin (Salama et al, 2014).
Senescent cells in culture are a highly heterogeneous population,
and these subpopulations consequently may present different
vulnerabilities to senotherapies and senoprobes. It is therefore
important that we ask the right clinical question (e.g. Does drug X
enhance the efficacy of drug Y in condition Z?) in the right model
that is as accurate a representation of the human condition as
possible.
Despite major advances, translation of senescence targeting to
the clinic should be approached with caution, since senescence
plays both beneficial and detrimental roles depending on the patho-
logical context (Mun˜oz-Espı´n & Serrano, 2014) and it is crucial that
we examine this thoroughly in appropriate preclinical models. It is
well known that cell senescence prevents the expansion of damaged
and pre-malignant cells in a cell autonomous manner, and hence, it
is an important barrier against tumorigenesis (Collado & Serrano,
2010). This correlates with the observation that, among other senes-
cence-related genes, the vast majority of human cancer cells accu-
mulate mutations in the p53-p21 and/or the p16-Rb axis (Vergel &
Carnero, 2010). A relevant concern is that bypassing or reversing
senescence could indeed promote tumorigenesis (Krimpenfort et al,
2001). Accordingly, there is evidence that particular populations of
therapy-induced senescent cancer cells can acquire phenotypic and
functional stemness features, resulting in cell cycle re-entry, self-
renewal capacity and a more aggressive tumour phenotype (Mila-
novic et al, 2018). This is less critically important in the context of
attempts to improve treatments for patients with advanced cancer
where more risk is often ethically acceptable, but nonetheless this
requires close interrogation in preclinical models.
Besides cell autonomous roles, the SASP is crucially implicated
in the recruitment of T cells and macrophages facilitating immuno-
surveillance in liver precancerous lesions (Burton & Stolzing, 2018)
although the senescent secretome may also be endowed with an
intrinsic potential to promote chronic inflammation and tumour
progression (Gonzalez-Meljem et al, 2018). It is known that the
SASP facilitates tissue repair in disorders caused by severe damage
and injury. This is the case for senescent activated stellate cells,
capable of limiting liver fibrosis by a reduced secretion of extracellu-
lar matrix components, enhanced secretion of extracellular matrix
degrading enzymes and increased immunosurveillance (Krizha-
novsky et al, 2008). In addition, senescent fibroblasts accumulate in
granulation tissues of healing cutaneous wounds and express antifi-
brotic genes (Jun & Lau, 2010). Senescence, however, intriguingly
mediates fibrotic pulmonary disease, and removal of senescent cells
using senolytics, therapeutic nanoparticles and anti-inflammatory
compounds reverts fibrosis and improves lung function in mice
(Hecker et al, 2014; Lehmann et al, 2017; Schafer et al, 2017;
Mun˜oz-Espı´n et al, 2018). The antagonistic roles of cell senescence
in a number of mouse models of human fibrotic diseases highlight
the importance of a more detailed understanding of the triggers,
intrinsic mechanisms and pathways driving the stable cell cycle
arrest and distinct factors secreted by senescent cells before wide-
spread clinical trials, particularly in otherwise healthy populations.
Therefore, the development of appropriate and more accurate
animal disease models capable of ensuring a causative role of senes-
cence and specific beneficial effects of its manipulation is still a
priority before definitively moving into clinical development, with
judicious assessment of predicted beneficial/toxic effects of investi-
gational strategies. Moreover, due to significant differences between
humans and mice, preclinical studies will require a more detailed
characterization of the peculiarities and mechanisms of action of
senescence in patients, along with a more extensive validation of
senotherapies and senoprobes by using specimens of human tissue
ex vivo and xenografts in mice (with fully humanized immune
systems), to prioritize the most promising disease-specific candi-
dates for clinical application.
The need to develop specific biomarkers of senescent cells
remains a limiting factor for efficient translation of strategies target-
ing senescence. SASP components and the associated immunoregu-
lation could provide tools for the selection of patients (in a
biomarker-directed manner) and for assessing sensitivity or resis-
tance to senotherapies (and to help drive further clinical develop-
ment of on-target, pharmacodynamically active therapeutics).
These include screening, diagnostic, monitoring, prognosis and
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pharmacodynamic tools. In the case of senotherapies, pharmacody-
namic biomarkers are keys in measuring the on-target responses
and are crucial for dose optimization studies. Unfortunately, there is
currently no universal marker for cellular senescence available
(Sharpless & Sherr, 2015), and quantitative methods in basic
research have been limited to cytochemical protocols and flow
cytometry analyses (Debacq-Chainiaux et al, 2009; Biran et al,
2017). One of the first methodologies to image and monitor senes-
cence noninvasively in vivo was based on a sequential reporter-
enzyme bioluminescence technology to track b-gal activity by using
Lugal, a caged galactoside-luciferin conjugate (Wehrman et al,
2006). Recent studies validated the use of nanoparticles and fluores-
cent probes to target senescent cells in mouse models (Lozano-
Torres et al, 2017; Mun˜oz-Espı´n et al, 2018; Wang et al, 2019).
Nanoparticles open up the possibility of encapsulating tracers and
contrast agents for the imaging of senescence location and burden,
and to be used as imaging biomarkers to direct promising therapies
to populations most likely to benefit from them. This will however
require the adaptation of current preclinical tools to deep tissue
penetration bioimaging techniques. For example, diagnostic GalNPs
could release gadolinium or positron-emitting radioisotopes in
senescent lesions to allow detection by MRI or PET, respectively.
Gal-encapsulation methods and senoprobes could also serve to
monitor the response of solid tumours to the administration of
senescence-inducing chemotherapies, or the senescence burden in
patients with senescence-associated disorders, before and after
senotherapy to provide a pharmacodynamic biomarker of response.
In addition to cancer and other chronic pathologies, cellular senes-
cence is a defining feature of a wide variety of human pre-malignant
lesions (Collado & Serrano, 2010). Based on this, it is tempting to
speculate that GalNPs and senoprobes could be utilized in the early
diagnosis of pre-malignant tumours. Senescence-specific NPs could
also potentially be employed as theranostic tools, aimed at the
simultaneous detection and eradication of senescent lesions associ-
ated with numerous pathologies, or during ageing. The latter would
likely require regular, intermittent interventions to eliminate senes-
cent cells or to manipulate a damaging SASP, while minimizing off-
target effects in normal cells and on-target manipulation of benefi-
cial senescent cells.
Beneficial senescent cells are plentiful, but biomarkers and drug
sensitivities that might distinguish these from pathological senescent
cells are lacking. Cellular senescence contributes centrally to the
physiological processes of (i) repair, facilitating wound healing
through secretion of platelet-derived growth factor AA (Demaria
et al, 2014); (ii) regeneration, promoting tissue reprogramming of
nearby cells in the context of injury and ageing (Mosteiro et al,
2016; Chiche et al, 2017; Ritschka et al, 2017) including limb
regrowth in salamanders (Yun et al, 2015); and (iii) embryonic
development, playing an active role in tissue remodelling and
morphogenesis (Mun˜oz-Espı´n et al, 2013; Storer et al, 2013). The
potential targeting of beneficial senescent cells remains unexplored
in the context of senotherapies and senoprobes, not helped by the
short lifespans of the widely used animal models. Manipulation of
cell senescence during these processes may compromise patient
health. In this regard, there are several possible strategies to over-
come this problem and optimize selectivity. An important approach
will be the development of second generation versions of pharmaco-
logically active compounds and probes already tested in preclinical
studies but which target pathological senescent cells specifically,
exploiting synthetic lethal vulnerabilities. Another emerging possi-
bility to increase specificity is to modify the therapeutic or diagnos-
tic agent to be activated by an external stimulus or enzymatic
reaction. This is the case for galactose-based nanoparticles, encapsu-
lation methods and probes (Agostini et al, 2012; Lozano-Torres
et al, 2017; Thapa et al, 2017; Mun˜oz-Espı´n et al, 2018), which are
preferentially activated by the increased lysosomal b-gal function of
senescent cells. Alternatively, accumulation of SASP components
and enzymes in the senescent intercellular space might also be
employed to stimulate drug delivery systems and inactive pro-seno-
lytics, or activatable probes, for imaging. Ideally, synthetically lethal
compounds would be loaded into nanocarriers targeting senescent
(or even pathologically senescent) cells, thereby extensively widen-
ing their therapeutic windows. This will require a more detailed
information of the diseased cell-specific signalling pathways and
vulnerabilities at the mechanistic level.
In the absence of such data, we should still move forward with the
knowledge we have. More refined BCL-2 family inhibitors capable of
preventing dose-limiting toxicities, such as thrombocytopenia and
neutropenia (Cang et al, 2015) should be tested. In the case of nano-
medicine, translational applications potentially have significant long-
term safety concerns, and it is important to understand the cellular
uptake and intracellular trafficking of specific NPs, biocompatibility
and biodistribution properties, PK/PD analyses and routes of elimina-
tion of the core materials, which heavily rely on their physicochemi-
cal properties. For instance, opsonin binding can trigger recognition
and clearance by the mononuclear phagocyte system and accumula-
tion of NPs in liver and spleen (Mahmoudi et al, 2011), with the
potential for sequestration and long-term toxicity.
Other alternatives might include strategies based on the adminis-
tration of combinations of senotherapies (such as mTOR inhibitors
with other senescence modulating drugs (Han et al, 2015), poten-
tially reducing required doses of each agent and off-target effects),
or the use of direct routes of administration to directly target the
senescent tissue or organ and reduce exposure of non-targeted
tissues. Examples include inhalation of aerosols for pulmonary drug
delivery, or preparations of injectable formulations of senotherapies
for in situ treatments. Current studies are focusing on the identifi-
cation of specific epitopes, proteins and surface receptors in senes-
cent cells, which would facilitate the design of antibody-based
therapeutic or diagnostic formulations with increased selectivity and
reduced side effects. Some of the identified potential markers, such
as DEP1 and B2MG (Althubiti et al, 2014), or DCR2 (Collado et al,
2005), although overexpressed in senescent cells are also present in
other cells and damaged tissues. A possible target is surface DPP4,
which is preferentially expressed in senescent but not proliferating
human diploid fibroblasts (Kim et al, 2017b). A recent in vitro study
employs CD9 receptors in combination with increased SAbgal activ-
ity, for dual NP targeting and drug delivery in senescent cells
(Thapa et al, 2017), but further studies in vivo are required to
demonstrate the translational applications of these approaches.
Short or intermittent exposures to senotherapies may also decrease
their potential of driving adverse effects while maintaining their
therapeutic benefits. This might be particularly relevant in treat-
ments aimed at maintaining tissue homeostasis and function, and to
delay ageing. However, it remains unclear how to justify preventa-
tive senotherapies outside the context of disease. Extensive
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preclinical testing will have to be completed before moving clinical
trials towards otherwise healthy populations.
Besides the aforementioned strategies to manipulate cell senes-
cence, other emerging features of senescent cells may be used to
develop novel therapeutics, biomarkers and/or diagnostic tools in
the near future. Senescent cells and SASP factors are accompanied
by a significantly increased release of extracellular vesicles and
exosomes (Lehmann et al, 2008) containing proteins, lipids and
microRNAs, affecting nearby tissue and potentially having relevant
roles in immune regulation (Xu & Tahara, 2013; Urbanelli et al,
2016; Borghesan et al, 2019). Small exosome-like extracellular vesi-
cles can be important mediators of the pro-tumorigenic functions of
the senescent secretome. This process involves extracellular vesicle-
associated EphA2 secreted from senescent cells, which binds to
ephrin-A1 that is highly expressed in several cancer cell types and
promotes proliferation (Takasugi et al, 2017). Exosomes released by
senescent prostate cancer cells subjected to radiation therapy were
enriched in B7-H3 protein, an immune checkpoint ligand. It is
tempting to speculate that manipulation and identification of extra-
cellular vesicles secreted by senescent cells might be used in (im-
muno)therapeutic approaches. Another interesting alternative to
modulate the SASP and the immune response could be through
modulation of the cGAS-cGAMP-STING signalling pathway. This
pathway detects cytoplasmic chromatin fragments in response to
DNA damage in senescent cells, activates type I interferons and
other cytokines, and mediates autoinflammatory diseases (Li &
Chen, 2018). Cyclic guanosine monophosphate (GMP)–adenosine
monophosphate (AMP) synthase (cGAS) and the adaptor protein
STING are key drivers of the senescent secretome in primary human
cells and in mice (Dou et al, 2017; Glu¨ck et al, 2017; Yang et al,
2017). Mice deficient in cGAS and STING show impaired immuno-
surveillance of oncogenic RAS and reduced tissue inflammation
after ionizing radiation. Furthermore, this pathway is activated in
cancer cells and correlates with pro-inflammatory gene expression
in human cancers (Li & Chen, 2018). It is therefore reasonable to
explore novel therapeutic and/or diagnostic strategies based on the
manipulation of the cGAS-cGAMP-STING signalling pathway.
Several small-molecule antagonists of STING with efficacy in the
treatment of autoinflammatory disease in mice have already been
characterized (Haag et al, 2018).
The wealth of potential therapeutic targets that senescence
presents in disease are myriad. However, our study of the roles and
pathways of senescence in specific pathologies is much less
advanced. We advocate translational studies to elucidate these in
the human disease of interest, with appropriate preclinical valida-
tion of putative therapeutic strategies in appropriate models before
the strategies predicted to be most safe and efficacious are consid-
ered for clinical trials.
Concluding remarks
Global populations continue to age, increasing the prevalence of
chronic age-related pathologies, and producing an associated public
health epidemic. Senescent cells accumulate during ageing, causing
tissue dysfunction, and are associated with a wide variety of age-
related disorders, both in humans and animal models. Preclinical
studies have convincingly concluded that the elimination of senes-
cent cells can ameliorate and even revert the pathological manifesta-
tions of multiple disorders in mice (Fig 1). Many challenges must be
overcome to ensure successful translational application of strategies.
These include the need for: (i) a better understanding of the triggers
and signalling pathways driving the senescent arrest and the dif-
ferent secretomes in the context of a particular disease; (ii) the devel-
opment of more advanced and clinically relevant animal models
capable of distinguishing on-target from off-target effects for each
condition (Kirkland & Tchkonia, 2015); (iii) an increase in the selec-
tivity of senotherapies or senoprobes, to reduce known and potential
toxicities; (iv) solid experimental data concerning the biodistribution
properties, PK/PD modelling and routes of elimination of nanocarri-
ers; and (v) the optimization of the therapeutic/diagnostic window
of free/encapsulated senolytic agents/combinations. Owing to the
heterogeneity of patients and the complexity and multifactorial
nature of ageing and age-related disorders, it is likely that future
interventions against cellular senescence will be biomarker- and
context-dependent (personalized), where the risk–benefit ratio can
be more clearly understood. While surprisingly few early-phase clini-
cal studies on senotherapies have been initiated, we expect this to
balloon in coming years and hope that these are designed prudently.
We are entering an exciting era, where we will be able to move anti-
senescent therapies towards medical applications, a strategy that
may have important impacts on precision medicine, healing, tissue
repair, regeneration and, ultimately, on human longevity.
Expanded View for this article is available online.
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